Literature DB >> 27864823

Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity?

K R Vogel1, G R Ainslie1, P L Pearl2, K M Gibson1.   

Abstract

Vigabatrin (VGB; γ-vinylGABA) is a unique antiepileptic directly elevating CNS GABA via inactivation of the GABA metabolic enzyme GABA-transaminase. VGB is effective in treating infantile spasms, a rare seizure disorder associated with significant morbidity. The potential for unexplained bilateral constriction of the visual field associated with VGB intervention can severely limit its temporal utility. Removal of this potential adverse effect with adjuvant intervention(s) would represent a significant advance in epilepsy therapeutics.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27864823      PMCID： PMC5801739          DOI： 10.1002/cpt.581

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  5 in total

1.  mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.

Authors:  Kara R Vogel; Garrett R Ainslie; Michelle A Schmidt; Jonathan P Wisor; K Michael Gibson
Journal:  Pediatr Neurol       Date:  2016-10-03       Impact factor: 3.372

2.  Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.

Authors:  Robert C Sergott; Chris A Johnson; Kenneth D Laxer; Robert T Wechsler; Katya Cherny; JoAnn Whittle; Ge Feng; Deborah Lee; Jouko Isojarvi
Journal:  Epilepsia       Date:  2016-09-01       Impact factor: 5.864

3.  Optical coherence tomography to monitor vigabatrin toxicity in children.

Authors:  Catherine Origlieri; Brooke Geddie; Bethany Karwoski; Madison M Berl; Nancy Elling; William McClintock; Janet Alexander; Marlet Bazemore; Heather de Beaufort; Kelly Hutcheson; Marijean Miller; Jonathan Taylormoore; Mohamad S Jaafar; William Madigan
Journal:  J AAPOS       Date:  2016-04       Impact factor: 1.220

4.  Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse.

Authors:  Kara R Vogel; Garrett R Ainslie; Erwin E W Jansen; Gajja S Salomons; K Michael Gibson
Journal:  Ann Clin Transl Neurol       Date:  2015-04-17       Impact factor: 4.511

5.  Defects in GABA metabolism affect selective autophagy pathways and are alleviated by mTOR inhibition.

Authors:  Ronak Lakhani; Kara R Vogel; Andreas Till; Jingjing Liu; Sarah F Burnett; K Michael Gibson; Suresh Subramani
Journal:  EMBO Mol Med       Date:  2014-02-27       Impact factor: 12.137
  5 in total
  5 in total

1.  Clinical Pharmacology & Therapeutics: Past, Present, and Future.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

Review 2.  Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies.

Authors:  Kara R Vogel; Garrett R Ainslie; Dana C Walters; Alice McConnell; Sameer C Dhamne; Alexander Rotenberg; Jean-Baptiste Roullet; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2018-02-19       Impact factor: 4.982

3.  Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues.

Authors:  Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Neurochem Int       Date:  2019-02-26       Impact factor: 3.921

4.  Transcriptome analysis in mice treated with vigabatrin identifies dysregulation of genes associated with retinal signaling circuitry.

Authors:  Dana Walters; Kara R Vogel; Madalyn Brown; Xutong Shi; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Epilepsy Res       Date:  2020-06-20       Impact factor: 3.045

5.  Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Authors:  Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson
Journal:  Pharmacol Res Perspect       Date:  2019-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.